ethyl α-cyano-β-carbonylphenylbutyrate | 3288-56-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: ethyl α-cyano-β-carbonylphenylbutyrate
• 英文别名: 2-cyano-3-oxo-4-phenyl-butyric acid ethyl ester；2-Cyan-3-oxo-4-phenyl-buttersaeure-aethylester；γ-Phenyl-α-cyan-acetessigsaeure-aethylester；Phenacetylcyanessigsaeure-aethylester；Ethyl 2-cyano-3-oxo-4-phenylbutanoate；ethyl 2-cyano-3-oxo-4-phenylbutanoate
• CAS: 3288-56-0
• 化学式: C₁₃H₁₃NO₃
• 分子量: 231.251
• InChiKey: VOCXTYMPANHTAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  67.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl α-cyano-β-carbonylphenylbutyrate 、 苯胺 生成 2-氰基-4-苯基-乙酰乙酸苯胺
  参考文献：
  名称：

  Smith; Thorpe, Journal of the Chemical Society, 1907, vol. 91, p. 1903

  摘要：

  DOI：
• 作为产物：
  描述：

  苯乙酸 、 氰乙酸乙酯 在 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 以79%的产率得到ethyl α-cyano-β-carbonylphenylbutyrate
  参考文献：
  名称：

  一种α-氰基-β-羰基丙酸酯类化合物的制备方法

  摘要：

  本发明公开了一种α‑氰基‑β‑羰基丙酸酯类化合物的制备方法，所述方法为：以有机酸和氰基丙酸酯类化合物为原料，以N,N'‑羰基二咪唑为助剂，在溶剂中，于40～70℃下反应，反应完全后，反应液经后处理制得α‑氰基‑β‑羰基丙酸酯类化合物；本发明反应工艺简单，只需一步反应即可得到目标产物，反应温度低，时间短，且在常压下进行，无需高压设备，生产成本低，污染少，对环境友好。所得产物收率达78％以上，液相色谱检测纯度97％以上。本发明方法是适用于工业化生产的α‑氰基‑β‑羰基丙酸酯类化合物的制备方法。

  公开号：

  CN107573260A

文献信息

• Urushibara, vol. 3, p. 317
  作者：Urushibara

  DOI：——

  日期：——
• Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial
  作者：Thomas Reinhard、Alexander Reis、Daniel Böhringer、Michael Malinowski、Adina Voiculescu、Peter Heering、Erhard Godehardt、Rainer Sundmacher

  DOI：10.1007/s004170100285

  日期：2001.6

  Background: With the use of systemic cyclosporin A (CsA), graft prognosis after high-risk penetrating keratoplasty has improved considerably. However, the application of CsA is limited owing to a variety of severe side effects. In this prospectively randomized study mycophenolate mofetil (MMF), a safe and efficient immunosuppressive medication after renal transplantation, was compared with CsA after high-risk penetrating keratoplasty. Methods: Twenty-nine high-risk keratoplasty patients were treated with MMF 2 x 1 g daily; another 27 patients received CsA, aiming at blood trough levels of 120-150 ng/ml. Systemic immunosuppression was scheduled for 6 months. In both groups oral corticosteroids (fluocortolone 1 mg/kg) were administered for 3 weeks postoperatively. Results: During the first year after operation, no graft failure was recorded. Two years postoperatively 92%/82% and 3 years postoperatively 74%/69% of grafts were clear in the MMF and CsA group, respectively (Kaplan Meier P=0.33, log-rank test). In total, two graft failures were recorded in the MMF group and four in the CsA group. Three years postoperatively 53% of the grafts were rejection-free in the MMF group and 73% in the CsA group (Kaplan Meier P=0.46, log-rank test). Eight endothelial immune reactions were observed in the MMF group (three under systemic immunosuppression/five thereafter; six mild/two severe) and five in the CsA group (three under systemic immunosuppression/two thereafter; three mild/two severe). Side effects occurred in six patients under MMF and 11 under CsA. Conclusions: Concerning efficacy, no statistically significant difference between systemic MMF and systemic CsA administered for 6 months after high-risk penetrating keratoplasty could be shown. Systemic MMF was proven to be at least as safe as CsA. The main mechanism in improving graft survival is a shift from severe to milder endothelial immune reactions, as already demonstrated for CsA. Thus, MMF may become an alternative to CsA for immunosuppression after penetrating high-risk keratoplasty. About 2 years postoperatively, pharmacologically induced relative immunological tolerance slowly decreases. Therefore, longterm administration of systemic MMF should be evaluated in further studies.
• Smith; Thorpe, Journal of the Chemical Society, 1907, vol. 91, p. 1903
  作者：Smith、Thorpe

  DOI：——

  日期：——
• 一种α-氰基-β-羰基丙酸酯类化合物的制备方法
  申请人：浙江工业大学

  公开号：CN107573260A

  公开（公告）日：2018-01-12

  本发明公开了一种α‑氰基‑β‑羰基丙酸酯类化合物的制备方法，所述方法为：以有机酸和氰基丙酸酯类化合物为原料，以N,N'‑羰基二咪唑为助剂，在溶剂中，于40～70℃下反应，反应完全后，反应液经后处理制得α‑氰基‑β‑羰基丙酸酯类化合物；本发明反应工艺简单，只需一步反应即可得到目标产物，反应温度低，时间短，且在常压下进行，无需高压设备，生产成本低，污染少，对环境友好。所得产物收率达78％以上，液相色谱检测纯度97％以上。本发明方法是适用于工业化生产的α‑氰基‑β‑羰基丙酸酯类化合物的制备方法。